SoftOx Solutions

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-07-05 EDT			5-day change	1st Jan Change
0.0836 ^NOK	-3.69%		-45.36%	-97.42%

07-02	Softox Solutions as Announces CFO Changes	CI
07-02	Softox Solutions as Announces New Board and Leadership	CI

SoftOx Solution AS First Quarter 2024 report

June 28, 2024 at 01:01 am

Please find attached the first quarter 2024 report for SoftOx Solutions AS.

Click here for more information

Latest news about SoftOx Solutions

Softox Solutions as Announces CFO Changes	07-02	CI
Softox Solutions as Announces New Board and Leadership	07-02	CI
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2024	06-28	CI
Transcript : SoftOx Solutions AS - Special Call	04-18
SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-19	CI
SoftOx Solutions Seeks Extension of NOK40 Million Convertible Loan; Shares Jump	01-16	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding	01-10	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10-31	CI
SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-26	CI
SoftOx Solutions Faces Penalty from Oslo Børs	23-09-18	MT
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-21	CI
SoftOx Solutions AS announced that it has received NOK 15 million in funding	23-06-08	CI
Oslo Børs Places Seven Issuers in Penalty Bench over Public Disclosure Rule Violations	23-06-02	MT
SoftOx Solutions Launches Temporary Layoffs Amid Restructuring; Shares Down 29%	23-03-27	MT
Softox Solutions AS Announces Resignation of Kari Myren from the Board	23-03-24	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Softox Solutions Announces Signing of the Final Grant Agreement for the Counteract Consortium	23-01-09	CI
SoftOx Solutions Appoints Interim CEO, New CFO	22-12-20	MT
SoftOx Solutions AS Appoints Christian Harstad as the Interim Chief Executive Officer	22-12-19	CI
SoftOx Solutions AS Announces Chief Financial Officer Changes	22-12-19	CI
Softox Solutions AS Announces Final Report Reaffirms Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	22-12-14	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26	CI
Softox Solutions Receives Swedish Approval For Disinfect Product	22-10-19	MT
Softox Solutions AS Announces Approval from the Swedish Chemicals Agency on Disinfection Products	22-10-18	CI

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

Sector

Biotechnology & Medical Research

Calendar

2024-09-03 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOFTOX SOLUTIONS	-97.42%	4.09M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B